BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ambrus C, Bakos É, Sarkadi B, Özvegy-Laczka C, Telbisz Á. Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. Sci Rep 2021;11:17810. [PMID: 34497279 DOI: 10.1038/s41598-021-97160-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Nwabufo CK, Bendayan R. Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends Pharmacol Sci 2022;43:1041-54. [PMID: 36374805 DOI: 10.1016/j.tips.2022.09.005] [Reference Citation Analysis]
2 Zhang J, He M, Xie Q, Su A, Yang K, Liu L, Liang J, Li Z, Huang X, Hu J, Liu Q, Song B, Hu C, Chen L, Wang Y. Predicting In Vitro and In Vivo Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity. ACS Omega 2022. [DOI: 10.1021/acsomega.2c05376] [Reference Citation Analysis]
3 Li X, Wang W, Yan S, Zhao W, Xiong H, Bao C, Chen J, Yue Y, Su Y, Zhang C. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019487] [Reference Citation Analysis]
4 Tsermpini EE, Glamočlija U, Ulucan-Karnak F, Redenšek Trampuž S, Dolžan V. Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review. Antioxidants (Basel) 2022;11:1609. [PMID: 36009328 DOI: 10.3390/antiox11081609] [Reference Citation Analysis]
5 Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, Wang X, Yang W, Qu H. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Front Pharmacol 2022;13:804189. [DOI: 10.3389/fphar.2022.804189] [Reference Citation Analysis]
6 Stefan SM, Jansson PJ, Pahnke J, Namasivayam V. A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors. Sci Data 2022;9:446. [PMID: 35882865 DOI: 10.1038/s41597-022-01506-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shih AR, Misdraji J. COVID-19: Gastrointestinal and Hepatobiliary Manifestations. Hum Pathol 2022:S0046-8177(22)00179-4. [PMID: 35843340 DOI: 10.1016/j.humpath.2022.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tuteja S, Yu Z, Wilson O, Chen HC, Wendt F, Chung CP, Shah SC, Hunt CM, Suzuki A, Chanfreau C, Gorman BR, Joseph J, Luoh SW, Napolioni V, Robinson-Cohen C, Tao R, Zhou J, Chang KM, Hung AM; VA Million Veteran Program COVID-19 Science Initiative. Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. Clin Transl Sci 2022. [PMID: 35684976 DOI: 10.1111/cts.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Merches K, Breunig L, Fender J, Brand T, Bätz V, Idel S, Kollipara L, Reinders Y, Sickmann A, Mally A, Lorenz K. The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. Arch Toxicol 2022. [PMID: 35579693 DOI: 10.1007/s00204-022-03306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Reiter RJ, Sharma R, Simko F, Dominguez-rodriguez A, Tesarik J, Neel RL, Slominski AT, Kleszczynski K, Martin-gimenez VM, Manucha W, Cardinali DP. Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04102-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
11 Wang F, Chen K, Chu S. Human/SARS-CoV-2 Genome-Scale Metabolic Modeling to Discover Potential Antiviral Targets for COVID-19. Journal of the Taiwan Institute of Chemical Engineers 2022. [DOI: 10.1016/j.jtice.2022.104273] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Shi B, Zhang Y, Huang B, Lin H, Zhou Q, Wang Y, Cai Z, Liu M. The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics. Molecules 2022;27:704. [PMID: 35163972 DOI: 10.3390/molecules27030704] [Reference Citation Analysis]
13 Kulkarni AV, Khelgi A, Sekaran A, Reddy R, Sharma M, Tirumalle S, Gora BA, Somireddy A, Reddy J, Menon B, Reddy DN, Rao NP. Post-COVID-19 Cholestasis: A Case Series and Review of Literature. J Clin Exp Hepatol 2022;12:1580-90. [PMID: 35719861 DOI: 10.1016/j.jceh.2022.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. Front Pharmacol 2021;12:704205. [PMID: 34867318 DOI: 10.3389/fphar.2021.704205] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
15 Spanakis M, Patelarou A, Patelarou E, Tzanakis N. Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments. Int J Environ Res Public Health 2021;18:11711. [PMID: 34770225 DOI: 10.3390/ijerph182111711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]